

INVITATION

THURSDAY

12
MAY

18:00 – 18:30
CET

GITMO 2022 NATIONAL MEETING

Benefits of ECP in the early stages of the treatment pathway for steroid-refractory GvHD

Royal Hotel Carlton, Bologna, Italy

This information is intended for Health Care Professionals in Europe

18:00 – 18:20 **Benefits of ECP in the early stages of the treatment pathway for steroid-refractory GvHD**

Prof. Attilio Olivieri, Università Politecnica delle Marche, Italy

18:20 – 18:30 **Q&A**

All

ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.

Follow the Therakos
Institute on LinkedIn



[Privacy policy](#)

For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2022 Mallinckrodt. Item code: EU-2200018. Date of preparation: January 2022.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides additional information.